Neuroaxial Prophylaxis for CABG

Consequences of Using Thoracic Epidural Analgesia for Coronary Artery Bypass Grafting

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04244435

Enrollment

300

Registered

2020-01-28

Start date

2020-02-01

Completion date

2022-01-31

Last updated

2021-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Occlusion

Keywords

coronary artery bypass grafting, prevention of complication, neuroaxial prophylaxis, thoracic epidural analgesia

Brief summary

Investigators plan to study the effect of thoracic epidural analgesia on postoperative parameters (complication rate, duration of hospitalization, mortality, etc.) of coronary artery bypass grafting.

Detailed description

Investigators plan to conduct a comparative analysis of early postoperative complications of coronary artery bypass grafting with and without cardiopulmonary bypass in patients with independent risk factors for the development of postoperative complications (advanced age, diabetes mellitus, chronic kidney disease, obesity, chronic obstructive pulmonary disease) with various types of anesthesiology benefits (general anesthesia and thoracic epidural analgesia versus general anesthesia and opioids). Investigators predict a decrease in the risk of developing cardiac, respiratory, infectious and renal complications, a reduction in the duration of intensive care, inpatient treatment and mortality.

Interventions

PROCEDURECABG

coronary artery bypass grafting with and without cardiopulmonary bypass

DRUGthoracic epidural analgesia

thoracic epidural analgesia at the level of 1-10 thoracic vertebrae (ropivacainum 0,2-0,5% 5-10 ml/h)

DRUGanalgesia of opioids

Opioids will be used for perioperative analgesia

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* coronary artery bypass grafting

Exclusion criteria

* Absolute contraindications for the use of thoracic epidural analgesia

Design outcomes

Primary

Measure	Time frame
hospital mortality	1 year
Hospitalization duration	1 year
Duration of treatment in the intensive care unit	up to 1 year

Secondary

Measure	Time frame
Complications	1 year

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026